NCT02015208View on ClinicalTrials.gov

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Ruxolitinib

20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.

Trial Locations (1)

M4N3M5

Sunnybrook Odette Cancer Center, Toronto

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER